MedTrace Logo

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

NCT00195689 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2007-08-29

No results posted yet for this study

Summary

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis

Conditions

Interventions

BIOLOGICAL

Human anti-TNF monoclonal antibody/adalimumab

Sponsors & Collaborators

Principal Investigators

  • Beverly Paperiello · Abbott

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31

Countries

  • United States

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00195689 on ClinicalTrials.gov